Table 6 Incremental cost-effectiveness ratios, healthcare perspective, 0 to 6 months
Incremental cost | Incremental effect | ICER | |||||
|---|---|---|---|---|---|---|---|
Mean; (95% bootstrap CI) | Mean; (95% bootstrap CI) | ||||||
CBT versus TAU | |||||||
Completers ( N =152) | |||||||
QALY (EQ-5D) | -1,577.6 | -2,601.8 | -553.4 | 0.01 | -0.00 | 0.03 | CBT dominant |
EQ VAS | -1,583.8 | -2,606.9 | -560.7 | 6.19 | 3.63 | 8.75 | CBT dominant |
ITT ( N =168) | |||||||
QALY (EQ-5D) | -1,632.6 | -2,744.6 | -520.7 | 0.02 | -0.00 | 0.03 | CBT dominant |
EQ VAS | -1,635.0 | -2,747.6 | -522.3 | 6.33 | 3.59 | 9.07 | CBT dominant |
PPA ( N =154) | |||||||
QALY (EQ-5D) | -1,773.5 | -2,924.9 | -622.1 | 0.02 | -0.00 | 0.03 | CBT dominant |
EQ VAS | -1,775.1 | -2,927.6 | -622.7 | 6.58 | 3.83 | 9.33 | CBT dominant |
CBT versus RPT | |||||||
Completers ( N =152) | |||||||
QALY (EQ-5D) | -1,866.8 | -2,917.6 | -816.0 | 0.01 | -0.00 | 0.03 | CBT dominant |
EQ VAS | -1,870.8 | -2,921.6 | -819.9 | 3.52 | 1.13 | 5.91 | CBT dominant |
ITT ( N =168) | |||||||
QALY (EQ-5D) | -1,804.0 | -2,786.7 | -821.3 | 0.01 | -0.00 | 0.03 | CBT dominant |
EQ VAS | -1,805.4 | -2,788.6 | -822.2 | 3.61 | 1.08 | 6.15 | CBT dominant |
PPA ( N =154) | |||||||
QALY (EQ-5D) | -1,972.8 | -3,008.2 | -937.5 | 0.01 | -0.00 | 0.03 | CBT dominant |
EQ VAS | -1,973.7 | -3,011.3 | -936.1 | 3.93 | 1.35 | 6.52 | CBT dominant |
RPT versus TAU | |||||||
Completers ( N =152) | |||||||
QALY (EQ-5D) | 289.2 | -858.1 | 1,436.5 | -0.00 | -0.02 | 0.01 | TAU dominant |
EQ VAS | 287.0 | -857.3 | 1,431.2 | 2.67 | 0.55 | 4.79 | 107 |
ITT ( N =168) | |||||||
QALY (EQ-5D) | 171.4 | -1,037.3 | 1,380.0 | 0.00 | -0.01 | 0.02 | 98,434 |
EQ VAS | 170.4 | -1,037.1 | 1,377.9 | 2.72 | 0.42 | 5.02 | 63 |
PPA ( N =154) | |||||||
QALY (EQ-5D) | 199.3 | -1,023.0 | 1,421.6 | 0.00 | -0.01 | 0.02 | 107,697 |
EQ VAS | 198.6 | -1,022.6 | 1,419.7 | 2.65 | 0.35 | 4.94 | 75 |